Spending Caps: A Desperate Measure?
This article was originally published in RPM Report
Executive Summary
A few biotech manufacturers are beginning to explore ways to address the high cost of their products-including the use of some surprising tactics. Genentech and ImClone are considering what is essentially self-imposed spending caps. But given that managed care has a hard time putting use restrictions on oncology products like Genentech's Avastin, the move would be largely an effort to stem political concerns about the high cost of specialty drugs.